Sugi Predict

Sugi Predict / Compounds / SCHEMBL9921691

SCHEMBL9921691

SCHEMBL9921691

Cc1ccc(NC(=O)CN2CCOCC2)cc1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.76
▸ LMNA P02545 1/20 0.75
▸ SMN1; SMN2 Q16637 1/20 0.75
▸ ALDH1A1 P00352 8/20 0.74
▸ HPGD P15428 3/20 0.74
▸ ALOX15 P16050 1/20 0.74
▸ KDM4E B2RXH2 1/20 0.69
▸ TSHR P16473 1/20 0.69
▸ HRH3 Q9Y5N1 1/20 0.68
▸ CA1 P00915 1/20 0.68
▸ CA2 P00918 1/20 0.68
▸ CA9 Q16790 1/20 0.68
▸ NPC1 O15118 1/20 0.65
▸ USP2 O75604 1/20 0.65
▸ GLA P06280 1/20 0.64
▸ HTT P42858 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102349 0.87 ATM (0.75) ATMLMNASMN1; SMN2HPGDALOX15
SCHEMBL13025526 0.86 ATM (0.74) ATMLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL6555426 0.86 ALDH1A1 (0.80) ATMLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL403057 0.86 ATM (0.74) ATMLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL3216808 0.86 ATM (0.74) ATMLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL10122851 0.86 LMNA (1.00) ATMLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL22793773 0.85 ATM (0.68) ATMLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL21671899 0.85 ATM (0.68) ATMLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL22793764 0.85 ATM (0.68) ATMLMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL4185215 0.85 ALDH1A1 (0.71) ATMLMNASMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017040993-A1 SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2017-03-09 — — WO disclosed
EP-2417140-B1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INT (DE) 2014-11-26 — — EP disclosed
US-8653282-B2 Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 — — US disclosed
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 — — US disclosed
US-8349839-B2 Inhibitors of HIV replication BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-08 — — US disclosed
US-8349839-B2 Inhibitors of HIV replication BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-08 — — US disclosed
EP-2010185-B1 DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS BOEHRINGER INGELHEIM INT (DE) 2012-06-13 — — EP disclosed
WO-2010115264-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 — — WO disclosed
US-20100261714-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 — — US disclosed
US-20100261714-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 — — US disclosed
US-20100222585-A1 PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 — — US disclosed
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS PTC THERAPEUTICS, INC. 2010-07-15 — — US disclosed
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2010-06-24 — — US disclosed
US-7601840-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2009-10-13 — — US disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES RNMT, VEGFA, VHL ATM 3586/4885LMNA 3138/4885SMN1; SMN2 1436/4885
US-20100222585-A1 PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN DPYD, TYMS, DHFR ATM 1503/4885LMNA 4078/4885SMN1; SMN2 1814/4885
US-20100261714-A1 INHIBITORS OF HIV REPLICATION RTF2, POLR1A, REV1 ATM 3417/4885LMNA 2404/4885SMN1; SMN2 4527/4885
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration VEGFA, FLT4, MIF ATM 4544/4885LMNA 3199/4885SMN1; SMN2 4645/4885
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS VEGFA, FLT4, PGF ATM 4447/4885LMNA 4374/4885SMN1; SMN2 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.